Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026)
Ocugen (OCGN) reported Amortization of Deferred Charges of $377000.0 for Q1 2026, up 25.67% on a YoY basis from $300000.0 in Q1 2025, and up 25.67% quarter-over-quarter from $300000.0 in Q1 2025.
Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Ocugen has reported Amortization of Deferred Charges for 3 years, with the latest figure at $377000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortization of Deferred Charges rose 25.67% year-over-year to $377000.0; the trailing twelve-month figure through Mar 2026 stood at $833000.0 (up 121.54% YoY), and the FY2025 full-year result was $1.4 million, up 8412.5% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $377000.0, up from $300000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $377000.0 in Q1 2026, with the low at $300000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ocugen | 411.07 Mn | 411.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 377,000.00 |
| Mar 31, 2026 | 377,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2014 | 77,000.00 |
| Dec 31, 2014 | 77,000.00 |
| Sep 30, 2014 | 79,000.00 |
| Sep 30, 2014 | 79,000.00 |
| Jun 30, 2014 | -80,000.00 |
| Jun 30, 2014 | -80,000.00 |
| Mar 31, 2014 | -38,000.00 |
| Mar 31, 2014 | -38,000.00 |